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Next-generation sequencing (NGS) has truly trans-
formed human genetics and is now an integral dis-
covery tool in the field. Whole-exome sequencing 
(WES) – an NGS application focused on the protein-
coding regions of the human genome – has already 
bridged the bench-to-bedside divide internationally and is offered as 
a clinical test by several accredited laboratories.[1,2] Clinical WES is not 
currently offered in South Africa (SA) for a number of reasons, including 
technological constraints, insufficient storage for the resulting large 
datasets, ethical considerations and limitations of our understanding 
of the impact of human genetic variants on health and in terms of 
clinical utility. The historical under-representation of individuals of 
black African descent in genomics research further complicates the 
interpretation of results obtained from WES data in black Africans.[3]
Concurrently, the application of WES for preventive healthcare 
in seemingly healthy individuals is progressing rapidly. WES offered 
as a direct-to-consumer (DTC) genetic test to healthy individuals in 
aid of wellness and future disease risk prediction raises many critical 
considerations, some of which were highlighted previously in the SAMJ by 
the Southern African Society for Human Genetics.[4] This topic is currently 
back in the headlines as local health insurance company Discovery Health 
launched their suite of personalised medicine products, which includes 
WES.[5-7] This offering is presented in partnership with US-based company 
Human Longevity, Inc. (HLI) under the leadership of J Craig Venter.
The benefits – improved health and 
precision medicine
Using genome-focused information to improve health outcomes has 
great potential. This endeavour could benefit South Africans directly, as 
it is a start to wide-scale research to unravel the genetic basis of diseases 
in all populations. Combining NGS data with detailed electronic medical 
and wellness records and family history is a powerful approach towards 
providing improved health and wellness. Indeed, this is the course that will 
be taken by President Barack Obama’s Precision Medicine Initiative,[8] led by 
the National Institutes of Health, and the Genomics England Initia tive. [9] 
Similar to these large public research initiatives, private enterprises such as 
HLI (Discovery’s partner) also strive to sequence millions of genomes in 
order to potentially fast-track drug discovery and improvement through 
partnerships with pharmaceutical companies. However, in this case it is 
with the stated additional purpose of commercial gain. Involving SA in this 
endeavour, and doing so as a DTC service to health insurance clients, raises 
important concerns, some of which we outline below.
Issues to consider relevant to the 
implementation of WES in SA
Owing to the comprehensiveness of WES data and our limited 
understanding of the impact of genetic variation on traits and diseases, 
the leading concern when dealing with WES in healthy individuals is 
the appropriate interpretation of results. The likelihood of identifying 
variants of unknown significance or disease-causing mutations linked to 
untreatable diseases is high. Interpreting these data in individuals from 
previously understudied populations (such as black African populations) 
further complicates interpretation. The analytical sensitivity and specificity 
of WES should also be considered – diagnostic laboratories offering 
clinical WES will validate positive findings with an alternative method 
before releasing diagnostic results. Owing to the uncertainty and concerns 
relating to the impact of results generated by WES on an individual’s health 
and wellbeing, guidelines have been established by various international 
professional groups, most notably the American College of Medical 
Genetics and Genomics.[10]
Closely linked to the uncertainty of data interpretation in WES is the 
need for adequate pre- and post-test counselling – a service that may be 
negated if WES is offered direct to the consumer. The health professionals 
best placed to provide these services are medical geneticists and genetic 
counsellors. In SA, genetic counsellors and medical geneticists are health-
care professionals registered with the Health Professions Council of South 
Africa as independent practitioners, with formal tertiary training in their 
respective professional fields. Both have a deep and broad knowledge of 
genetics, communication skills to inform and educate a variable audience 
on the complexities of genetics, psychosocial assessment abilities and 
the knowledge and ability to apply professional ethics. There is currently 
a limited number of them in SA, raising concerns that there would be 
insufficient capacity to provide proper information prior to testing, 
during informed consent and when test results are received.
The ethical implementation of WES is crucial and safeguarded by 
proper pre-test information sharing, counselling and informed con-
sent. Recommendations on what should be considered as part of this 
process are set out in Table 1. The Discovery/HLI WES offering will 
implement a broad consent model, with no option to opt out after 
consent is given, whereas the global trend is to move towards dynamic 
consent that enables greater participant engagement.[11,12] Post-test 
counselling for positive results must include practical guidance 
regarding preventive and therapeutic options, psychosocial support, 
and the offer of family follow-up. It is crucially important that an 
appropriate governance framework is in place that restricts exploitative, 
unapproved use of the data generated. What is important in that 
framework is that the interests of SA individuals and communities 
are appropriately considered when granting access to data. Lastly, it is 
strongly recommended that a local ethics committee review consent 
documentation and research proposals for this initiative. It would be 
expected that all these objectives will be in place and approved prior to 
any testing being offered to participants.
From a legal standpoint, there are many potential pitfalls when 
offering direct-to-consumer WES. Confidentiality, anti-discrimination 
and protection of personal information are principles that are embedded 
in our constitution and legislation. With regard to intellectual property, 
patenting of DNA sequences is not allowed – however, any new 
diagnostics and therapeutics developed through the use of DNA 
sequence data are patentable. Benefit sharing, which can take several 
forms, should be considered, particularly since participants are paying 
for the service, if only in part. These details could be included in a 
material transfer agreement. It should also be remembered that exomes 
contain a great deal of information beyond disease susceptibility, 
such as information about ancestry, admixture and so forth. This 
information needs to be managed with a great deal of care because 
of the repercussions it might have for individuals and communities 
involved, including a potential for discrimination. One way of ensuring 
that secondary use of genomic data is not harmful or exploitative, and 
that it takes appropriate recognition of contextual factors important 
in its interpretations, is to carefully govern access to data. There is 
now considerable experience with regulating access to genomic data 
globally that should be considered in the Discovery initiative. Managed 
access to primary data, i.e. limiting access to suitably qualified 
personnel, should be encouraged.
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A final point of consideration is the use of these data for research 
purposes. Exploitation of local DNA resources with a lack of 
significant engagement and local capacity development is a reality in 
the field of genomics, not only in SA but in Africa as a continent.[3,13,14] 
Although it has been stated that data would potentially be available 
to local scientists for research purposes, one has to wonder what 
competitive advantage African scientists will have to utilise these data 
fully, and whether it would ultimately lead to any kind of capacity 
development within the SA scientific community. If these date are 
simply to be used to help a US company to accumulate genome 
data in order to create a commercialisable private database of DNA 
and medical records, without any consideration for or intention of 
addressing urgent health and research needs of the SA population, 
this endeavour would raise real concern about exploitation.
In conclusion, there are a number of vitally important ethical, legal and 
scientific concerns that have to be addressed to ensure proper and ethical 
implementation of this service in SA and that individuals taking part in 
this endeavour are fully informed of the positive and negative sequelae.
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Table 1. Genetic counselling considerations when offering 
WES to healthy individuals
Exclusions
Healthy minors (<18 years) should be excluded.
Pre-test counselling
 The participant should be prompted to specifically consider the 
benefits, limitations and major concerns expected with WES results. 
Specifically, participants should be made aware:
 That the analysis performed will be for disease-causing variants 
in specific actionable genes
 Of the implications of a specific positive finding for further 
treatment – which may differ between individuals with a 
significant family history and those without
 Of the fact that such treatment may or may not be covered by 
medical aid, depending on the medical aid plan
 Of the implications of a positive finding for future applications 
for life insurance, and other possible social implications
Of the implications of a positive finding for other family members
 That WES will not detect all possible disease-causing variants, or all 
actionable variants
 That future assessment of the WES may detect significant 
variants at a later stage, even if nothing is detected initially
 Pre-test counselling should be done in person, if possible. At a minimum, 
the participant should have access to good-quality information, and to a 
genetic counsellor for important remaining queries.
 The cost of validation and counselling excluded from the 
sequencing pricing must be declared.
 A family history should be taken, and the participant should be 
informed of particular parts of the family history in which WES 
may be informative (e.g. things that appear to be due to single-
gene inheritance) and what parts of the family history are unlikely 
to provide information through WES (e.g. multifactorial disorders 
or those of unknown aetiology).
Reporting of results and post-test counselling
 Clinically relevant results should be validated, and reported to 
the participant by a health professional with appropriate genetics 
training (preferably a medical geneticist or genetic counsellor), 
especially if there is a positive finding.
